

Wastewater-based surveillance as an early warning tool to monitor infectious diseases at community level

Information Session – 27 June 2023

This session is being recorded.

Agenda

Торіс		Presenters
1	Opening remarks	Peter Sands Executive Director, The Global Fund to Fight AIDS, Tuberculosis and Malaria
2	Regional perspectives on environmental surveillance through wastewater-based surveillance	Yenew Kebede Tebeje Head, Laboratory Systems and Network Division and Acting Head, Division of Surveillance and Disease Intelligence, Africa CDC
3	Phase I: COVID-19 wastewater-based surveillance implementation	Noah Hull Laboratory Technical Manager, APHL
4	Updates • Ethiopia • Kenya • Mozambique	Daniel Abera Team Lead, Environmental Health Research Team, MOH/EPHI, Ethiopia Leonard Kingwara Head National Genomics and Molecular Surveillance Laboratory, MOH/NPHI, Kenya Natalia Ismael MOH/NIS, Mozambique
5	Phase II: Using NGS for multi-pathogen wastewater-based surveillance	Noah Hull Laboratory Technical Manager, APHL
6	Q&A	
7	Closing remarks	Shunsuke Mabuchi Head of RSSH, TAP, The Global Fund to Fight AIDS, Tuberculosis and Malaria

今 THE GLOBAL FUND



APHL Project Stellar: Wastewater-based Surveillance

Information Session 27 June 2023

Value of Testing Wastewater (WWBS)





APHL Project Stellar Objectives

- Support the development of testing capacity for SARS-CoV-2 in wastewater
- Technical assistance for validation of collection and testing protocol
- Technical assistance to improve data management and electronic test reporting system, including transfer from Laboratory Information Management Systems to epidemiology partners
- Support the use of data from WWBS surveys to complement case-based surveillance and monitor in-country trends
- Support and implement next-generation sequencing (NGS) of wastewater for SARS-CoV-2 and other pathogens of public health concern (e.g., AMR, VHF, pan-respiratory, etc.)



Ethiopia Case Study

Daniel Abera, Pl

Ethiopian Public Health Institute



የዜጎች ጤና ስሃንር ብልጽ ማና! HEALTHIER CITIZENS FOR PROSPEROUS NATION 27 June 2023



Project Timeline and Implementation

Phase and Timeline	Major activities	Accomplishments						
Phase I : May – June 2022 Assess laboratory readiness	 Tools developed, assessment of laboratory capability and capacity strengths, weaknesses, risks 	Gap analysis and country report completed						
Phase II:	Contract agreement and Stakeholders' engagement	MoU approved and TWG established						
July - January 2023 Strengthen lab capacity	 Develop protocol, work plans, SOPs, budget and timelines. 	All completed/ IRB certified protocol						
	Establish twining and training of staff	Staff capacity built						
	Procurement of equipment and supplies	Supplies procured for pilot testing						
Phase III: Feb 2023 – to date	Sample site assessment and selection	Completed						
Testing and result reporting:	Samples collection and test validation	Completed						
	Surveillance testing and report results	Ongoing						
	LIS and data management system	Ongoing						
	Genomic sequencing	Not started						

Methods and Study Areas

Study Site: Addis Ababa

 3 sites that represented different subcities and treatment technologies, were selected based on population served, flow rate, and/or suitability for the intended purpose.

Sampling design: Longitudinal design:

- Wastewater influent samples collected three time a week per site for a period of 8-9 months
- Sample size: 300



Sample Collection Sites - Population data

- 1) Kality Wastewater Treatment Plant (WTP)
 - A centralized and older plant in Ethiopia.
 - Estimated population size currently served could reach 2,000,000, mostly living in the northwestern part of Addis Ababa
- 2) Mikililand Waste Stabilization Pond
 - It serves nearly 4,634 houses with an estimated population of 24,000 in 'Condominium'
- 3) Bulbula Wastewater Treatment Plant
 - It serves nearly an estimated population of 34,000 living in 'Condominium'

Notes: Population size is received from Addis Ababa Water and Sewerage Authority.

Ethiopia: Sample Collection and Transportation

Installation of SWAB at WTP





Collection of SWAB after 24 hrs

Sample Transportation to EPHI Lab





Squeezing SWAB at EPHI Lab

Wastewater-based Samples Tested for SARS-CoV-2

Test results, February - June 2023



- High rate of SARS-CoV-2 detection suggests active and subclinical cases circulating in the community
- Further expansion and active surveillance and monitoring of trends needed
- There is a need to develop a strategy to integrate with the case-based surveillance



Project Stellar: Pilot of wastewater as a surveillance tool in Kenya

27 June 2023

Leonard Kingwara, PhD National Laboratory Services MoH Kenya

Challenges and Interventions

Challenges	Intervention
Unavailability of required supplies in country and delay in procurement process	Purchased and imported from Kenya
Limited budget for NGS supplies for pilot and future of WWBS	Pending-NGS supplies to be procured by Principal Recipient; Awaiting confirmation from PR.
Limited budget for personnel cost for NGS implementation for this pilot	Discussion ongoing with PR and EPHI to address the gap
Unclear lead time/ status for procurement delivery of NGS supplies	Continue to follow up with the PR and request GF advocacy on our behalf
Expansion of WWBS is a priority but constrained by limited resources	MOH/EPHI will address in GC-7 application and/or resource leverage

Lessons Learned

- Joint planning and coordination with surveillance and epidemiology units is paramount in ensuring success and sustainability
- Strong partnership and close working relationship with EPHI and APHL were critical for the implementation of the project
- Building local capacity through twinning with US-based institution
- Establishing TWG and engagement with key stakeholders
- Leveraging and use of existing in-country C19RM resources increased efficiency and cost-effectiveness
- The need to address procurement and supply chain system
- Allocation of sufficient resources for the expansion plan, including NGS



Wastewater-Based Surveillance Pilot Study Implementation

- NPHL began the WW pilot study in April 2022, bringing together stakeholders to create a workplan for implementation.
- Sampling and testing began in December 2022 at two collections sites in Nairobi
- Sample collection and detection
 - Samples collected: 98
 - Positivity rate: 80.6%
- Twinning between NGMSL and Wisconsin lab
 - Sample collection, testing and analysis methodology





What's Next...

- Study expansion from 2 to 17 sites
- Scale up of community testing
- WWBS sample sequencing (to include other pathogens of interest)



Wastewater-based Surveillance Results from the Pilot Sites

Trends in SARS-COV2 ORF1AB Gene in Wastewater in Nairobi



Laboratory Information System (LIS) Policy Changes: Pending Final Approval

This framework will help evaluate and choose the right LIS solutions systematically. It also provides a clear set of steps for implementation. It includes guidelines for defining strategic indicators and goals, determining data sources, and collecting information to make informed decisions.







Proposed Public Heath Response

- MoH Kenya is proposing to use WWBS data to scale up the use of Covid 19 of rapid test kit at the facilities/community level.
- A draft document has been produced which aims to outline the process of implementing public health responses from data on wastewater-based epidemiological surveillance of SARS CoV2 in Kenya with the aim of interrupting transmission and detecting any spike within the population.





Proposed Public Heath Response on WWBE





Lessons Learned from the Project Stellar Implementation:

- Scale up the implementation of wastewater-based surveillance in all 47 counties in Kenya to help **monitor pathogens of concerns in wastewater to detect outbreaks early** and provide a more comprehensive understanding of disease transmission.
- **WWBS enhanced collaboration between the lab and DDSR**. Translates to policy decisionmaking within the program from data generated. WWBS included as an Early Warning System for DDSR
- **Optimized data transmission and interoperability** with reduced patient identifier duplication and transcription errors allowing for longitudinal review of patient results.
- Established national ToTs to support LIS to sustain and track its usage.

Great Team and Motivated Staff



Great Leadership from Management and collaboration with MoH disease surveillance



Excellent Teamwork



The use of NGS for Waste Waster Surveillance in Mozambique: Way Forward

Instituto Nacional de Saúde (INS)

Nalia Ismael

Head of the Biotechnology Laboratory, INS





Surveillance of SARS-CoV-2 in Wastewater

Objective of current Pilot Validate the method of detection and quantification of SARS-CoV-2 from wastewater in 4 sites











March 21st Sample collection 4 sampling sites 2 samples/site/week

To Date: 113 Samples collected 91 Tested



Sample Collection and Data Sharing





NGS Implementation: Project Stellar

Overview

- Implement NGS testing for WWBS
- Detect and monitor <u>genetic changes</u> in SARS-CoV-2 with Illumina COVIDSeq Assay
 - Look for novel mutations that may confer virulence and immune-evasion
- Watch for and act to impede emerging health threats such as antimicrobial resistance

Implementation

- Assess laboratory needs to implement NGS
- Receive technical assistance for wet-bench and drybench trainings
- Data analysis using Terra.Bio bioinformatics tool
- Procurement of supplies and reagents to be done by the Principal Recipient (PR)
- Pandemic preparedness using targeted panels from Illumina



Benefits of NGS with WWBS



Public Health Laboratories Network and NGS Sequencing Capacity Created During the Pandemic



Road Map for Implementation of Integrated Genomic Surveillance in Mozambique







Future of WWBS

Noah Hull

Future of WWBS

- Future use of WW will be driven by country and MoH needs
- *Dynamic* field with evaluation by pathogen taking place now
- Expansion of WW sites within each of the countries
 - Actionable public health data expanded testing +/- public health messaging
- Targeted WWBS:
 - Aircraft (blue water)

Analysis. Answers. Action

- Communal living facilities
- One Health: livestock sites and wet markets



Future of WWBS – Other Select Pathogens

Agent	Urine	Feces	Sewage	Reference								
Enteric bacteria + AMR (<i>V. cholerae</i>)	Yes	Yes	Yes	Chahal et al. (2016)								
Enteroviruses	Yes	Yes	Yes	Maier et al. (2000); Poyry et al. (1994); Hovi et al. (1997)								
Нер А	Rare	Yes	Yes	Alter et al. (1977); Bancroft et al. (1977); Arvanitidou et al. (1998)								
Нер В	Rare	Yes	Yes	Dienstag et al. (1971); Alter et al. (1977); Bancroft et al. (1977); Arvanitidou et al. (1998)								
HIV	Yes	Yes	Yes	Levy (1989); Yolken et al. (1991)								
Human poliovirus	Yes	Yes	Yes	Jorba et al. (2017); Grassly et al. (2009); Nandy et al. (2016)								
Mycobacterium tuberculosis	Yes	Yes	Yes	Mtwtwa et al. (2022)								
Nipah virus	Yes	Yes	Yes	Chadha et al. (2006); Chua et al., (2002)								
Rabies	Yes	No	?	Wacharapluesadee and Hemachudha (2002)								
Viral encephalitis	Yes	Yes	?	Mathur et al. (1995)								



WWBS Expansion and Sustainability

- There is great enthusiasm from laboratory personnel and MOHs to implement WWBS and continue expansion to additional sites, NGS, and other pathogens.
- We would like to suggest The Global Fund consider alternative funding strategies that can better enable TA providers and laboratories to procure needed reagents and to appropriately scale up staffing as needed.
- We believe that this alternative funding strategy will ensure both sustainability and better funding absorption by directly providing the TA providers and labs the resources needed to implement/expand WWBS successfully.



Thank you!

- WWBS *is* the future of public health surveillance
- Labs in ~14 months have gone from ideation to sampling and testing
 - Wanting and have expanded the number of sites
 - Implemented public health actions
 - Prepared and eager to implement WWBS NGS testing
- As a leader in laboratory system strengthening, APHL remains committed to ensuring that WWBS is implemented to its full potential and looks forward to the possibility of expanding our work through strong partnerships with TGF, Africa CDC, and Country MoHs/Labs.



•	•	٠	٠	•	•	٠	•	•	•	•	•	•	•	•	•	•	•	•	•	٠	•	•	٠	•	•	•	•	•
•	•	٠	٠	•	•	•	•	٠	•	•	•	•	•	•	•	٠	•	٠	•	•	٠	•	•	•	•	•	•	•
•	•	•	٠	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•
·	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•
•	•	•	•	٠	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•			•
•	•	•	•	•	٠	•	•			•	•	•	•	•	•	•	•	•	•	•	•	•	•	•		•	•	•
		ha	'n	k	v		∎₹	•	e.			•	•	•		•	•	•		•			•	•	٠	•	•	•
	•		•	•	J,		•	•	2										•			•	•	•	•	•	•	•
	•	•	•	•	•	•	•	٠	*	a e	2						·					•	•	•	•	•	•	•
	•	•	•	•	•	•	•	•	•											•	•	•	•	•	•	٠	٠	•
	•	•	•	•	•	•	•	•												•	•	•	•	•	•	•	•	•
	•	•	•	•	•	•	•	•												•	•	•	•	•	•	•	•	
	•	•	•	•	•	•	•	•											•	•	•	•	•	•	•			
			TH		• • • •	•	•	•	The Glob AIDS, Tu	bal Fund t uberculosi	o Fight s and Ma	laria						•	•	•	•	•	•	•	•			
			FU	NC)•)•	•	•	•	+41 58 7 <u>thegloba</u>	91 1700 Ifund.org								•	•	•	•	•	•	•				
		•	•	•	•	•	•										•	•	•	•	•	•	•					